Man Group PLC Arcturus Therapeutics Holdings Inc. Transaction History

Man Group PLC

$37.6 Billion
Q2 2024

A detailed history of Man Group PLC transactions in Arcturus Therapeutics Holdings Inc. stock. As of the latest transaction made, Man Group PLC holds 16,790 shares of ARCT stock, worth $322,032. This represents 0.0% of its overall portfolio holdings.

Number of Shares

16,790

Previous 62,589 73.17%

Holding current value

$322,032

Previous $2.11 Million 80.69%

% of portfolio

0.0%

Previous 0.01%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$24.35 - $44.39 $1.12 Million - $2.03 Million	-45,799 Reduced 73.17%	16,790 $408,000
Q1 2024 May 15, 2024	SELL	$31.23 - $42.99 $746,834 - $1.03 Million	-23,914 Reduced 27.65%	62,589 $2.11 Million
Q4 2023 Feb 14, 2024	BUY	$17.71 - $32.97 $564,506 - $1.05 Million	31,875 Added 58.35%	86,503 $2.73 Million
Q3 2023 Nov 14, 2023	BUY	$25.44 - $37.35 $1.39 Million - $2.04 Million	54,628 New	54,628 $1.4 Million
Q1 2022 May 16, 2022	SELL	$17.64 - $39.57 $306,759 - $688,122	-17,390 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$34.2 - $47.56 $87,859 - $122,181	-2,569 Reduced 12.87%	17,390 $644,000
Q3 2021 Nov 15, 2021	BUY	$27.88 - $58.25 $75,108 - $156,925	2,694 Added 15.6%	19,959 $954,000
Q2 2021 Aug 16, 2021	SELL	$25.79 - $42.11 $46,705 - $76,261	-1,811 Reduced 9.49%	17,265 $584,000
Q1 2021 May 17, 2021	BUY	$38.75 - $86.92 $284,347 - $637,818	7,338 Added 62.51%	19,076 $788,000
Q4 2020 Feb 16, 2021	SELL	$34.61 - $123.66 $6,437 - $23,000	-186 Reduced 1.56%	11,738 $509,000
Q3 2020 Nov 16, 2020	BUY	$37.49 - $63.19 $447,030 - $753,477	11,924 New	11,924 $512,000

Others Institutions Holding ARCT

# of Institutions

188

Shares Held

27.6M

Call Options Held

320K

Put Options Held

153K

View Full List

About Arcturus Therapeutics Holdings Inc.

Ticker ARCT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,576,400
Market Cap $510M
Description
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lun...

More about ARCT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account